Search This Blog

Wednesday, January 22, 2020

Jazz Pharma submits marketing application for JZP-258

Jazz Pharmaceuticals (NASDAQ:JAZZ) has submitted a New Drug Application (NDA) to the FDA seeking approval for JZP-258 for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
The company redeemed its priority review voucher for the filing.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)